Griffin O’Driscoll is co-founder and Chief Executive Officer of Organicin Scientific, responsible for company strategy, partnerships, and translating the CinThesis platform into products for animal health and aquaculture. He brings a background in biochemistry, commercialization, and go-to-market execution for emerging life science technologies. Griffin holds a BS in Biochemistry from the University of Massachusetts Amherst and a Master of Management Studies from Boston University.

Peg Riley, Ph.D., is a microbiologist and evolutionary biologist whose work has shaped the modern understanding of bacteriocins and microbial competition. Before co-founding Organicin Scientific, she served as a Professor of Biology at the University of Massachusetts Amherst, where her research focused on antimicrobial peptides, microbial ecology, and pathogen evolution. Earlier in her career, she held faculty positions and research fellowships across leading institutions. Peg earned her Ph.D. from Harvard University and is internationally recognized for pioneering work on targeted antimicrobial approaches that preserve microbiome health.

Mathew Mitchell is co-founder and Chief Technology Officer at Organicin Scientific, where he leads development of the CinThesis discovery engine and the company’s bacteriocin design strategy. His work sits at the intersection of biophysics, computation, and translational microbiology, with a focus on building practical tools for precision antimicrobials. Mathew earned a master’s degree in Biophysics from Georgetown University and is currently completing his MD at Drexel University; he is also a Fulbright Scholar registering clinical trials exploring the microbiome in noninfectious disease at Semmelweis University, Budapest.